1. |
Kim KE, Song H, Kim TS, et al. Interleukin-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines[J]. Oncogene, 2007, 26(10): 1468-1476.
|
2. |
Kang JS, Bae SY, Kim HR, et al. Interleukin-18 increases metastasis and immune escape of stomach cancer via the downregulation of CD70 and maintenance of CD44[J]. Carcinogenesis, 2009, 30(12): 1987-1996.
|
3. |
Nong SJ, Zhang YP, Zhou SJ, et al. Relationship between serum IL-18 and VEGF levels in patients with prostate cancer[J]. Chinese-German J Clin Oncol, 2010, 9(11): 643-647.
|
4. |
Tsuboi K, Tatsuya M, Nakajima M, et al. Serum interleukin-12 and interleukin-18 levels as a tumor marker in patients with esophageal carcinoma[J]. Cancer Lett, 2004, 205(2): 207-214.
|
5. |
Jebreel A, Mistry D, Loke D, et al. Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer[J]. J Laryngol Otol, 2007, 121(3): 246-252.
|
6. |
Park H, Byun D, Kim TS, et al. Enhanced IL-18 expression in common skin tumors[J]. Immunol Lett, 2001, 79(3): 215-219.
|
7. |
Vidal-Vanaclocha F, Mendoza L, Telleria N, et al. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression[J]. Cancer Metastasis Rev, 2006, 25(3): 417-434.
|
8. |
Xia D, Zheng S, Zhang W, et al. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen[J]. J Mol Med, 2003, 81(9): 585-596.
|
9. |
Okamura H, Tsutsui H, Kashiwamura S, et al. Interleukin-18: a novel cytokine that augments both innate and acquired immunity[J]. Adv Immunol, 1998, 70: 281-312.
|
10. |
Marshall DJ, Rudnick KA, Mccarthy SG, et al. Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine[J]. Vaccine, 2006, 24(3): 244-253.
|
11. |
Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF[J]. Science, 1999, 284(5422): 1994-1998.
|
12. |
Asahara T, Kalka C, Isner JM, et al. Stem cell therapy and gene transfer for regeneration[J]. Gene Ther, 2000, 7(6): 451-457.
|
13. |
Rafii S. Circulating endothelial precursors: mystery, reality, and promise[J]. J Clin Invest, 2000, 105(1): 17-19.
|
14. |
Conti CJ. Vascular endothelial growth factor: regulation in the mouse skin carcinogenesis model and use in antiangiogenesis cancer therapy[J]. Oncologist, 2002, 7 Suppl 3(3): 4-11.
|
15. |
Bandoh N, Hayashi T, Takahara M, et al. VEGF and bFGF expression and microvessel density of maxillary sinus squamous cell carcinoma in relation to p53 status, spontaneous apoptosis and prognosis[J]. Cancer Lett, 2004, 208(2): 215-225.
|
16. |
Cho ML, Jung YO, Moon YM, et al. Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways[J]. Immunol Lett, 2006, 103(2): 159-166.
|
17. |
Amin MA, Rabquer BJ, Mansfield PJ, et al. Interleukin 18 induces angiogenesis in vitro and in vitro via Src and Jnk kinases[J]. Ann Rheum Dis, 2010, 69(12): 2204-2212.
|
18. |
Grimm D, Bauer J, Ulbrich C, et al. Different responsiveness of endothelial cells to vascular endothelial growth factor and basic fibroblast growth factor added to culture media under gravity and simulated microgravity[J]. Tissue Eng Part A, 2010, 16(5): 1559-1573.
|
19. |
Qiao H, Sonoda KH, Sassa Y, et al. Abnormal retinal vascular development in IL-18 knockout mice[J]. Lab Invest, 2004, 84(8): 973-980.
|
20. |
Qiao H, Sonoda KH, Ikeda Y, et al. Interleukin-18 regulates pathological intraocular neovascularization[J]. J Leukoc Biol, 2007, 81(4): 1012-1021.
|
21. |
Günel N, Co?kun U, Sancak B, et al. Clinical importance of serum interleukin-18 and nitric oxide activities in breast carcinoma patients[J]. Cancer, 2002, 95(3): 663-667.
|
22. |
Crohns M, Saarelainen S, Laine S, et al. Cytokines in bronchoalveolar lavage fluid and serum of lung cancer patients during radiotherapy-association of interleukin-8 and VEGF with survival[J]. Cytokine, 2010, 50(1): 30-36.
|
23. |
Coskun U, Gunel N, Sancak B, et al. Effect of tamoxifen on serum IL-18, vascular endothelial growth factor and nitric oxide activities in breast carcinoma patients[J]. Clin Exp Immunol, 2004, 137(3): 546-551.
|
24. |
Merendino RA, Gangemi S, Ruello A, et al. Serum levels of interleukin-18 and sICAM-1 in patients affected by breast cancer: preliminary considerations[J]. Int J Biol Markers, 2001, 16(2): 126-129.
|
25. |
Carbone A, Vizio B, Novarino A, et al. IL-18 paradox in pancreatic carcinoma: elevated serum levels of free IL-18 are correlated with poor survival[J]. J Immunother, 2009, 32(9): 920-931.
|